Loading...
  • Therapy
  • Consolidation therapy followed by stem cell rescue repeats every 28 days for 3 courses (C) and 3D-CRT to the brain (and the spine if needed) 5 days a week for 5-6 weeks (R), the order of which depends on patient age, in the absence of disease progression or unacceptable toxicity. (clinicaltrials.gov)
  • tumor
  • RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. (clinicaltrials.gov)
  • Eradication of low tumor burdens can occur in vivo when T-cell mediated responses are generated against specific tumor antigens. (clinicaltrials.gov)
  • Peptides derived from these fusion proteins have been shown to function as tumor antigens for cytolytic T cells in animal studies. (clinicaltrials.gov)
  • Merging these concepts, this protocol will attempt to eradicate minimal residual disease in pediatric patients with metastatic ESFT and AR via vaccination with tumor-specific peptides undertaken concomitant with autologous T cell transplantation and indinavir. (clinicaltrials.gov)
  • pure red cel
  • Autoimmune hemolytic anemia or pure red cell aplasia, AIHA: Hemolytic anemia Hemoglobin less than 10.0 g/dL without transfusion Hemolysis as evidenced by both: Sustained reticulocytosis (greater than 125,000/mm3) without evidence of active bleeding or increasing hemoglobin Laboratory evidence of hemolysis Positive direct antiglobulin test or equivalent immune adherence test No evidence for paroxysmal nocturnal hemoglobinuria Negative Ham's test and sucrose hemolysis. (clinicaltrials.gov)
  • acute
  • CNS prophylaxis: Beginning at least 2 months after transplantation, patients with acute lymphocytic leukemia (ALL) and no history of CNS leukemia receive cytarabine intrathecally (IT) monthly for 6 months and patients with ALL and a history of CNS leukemia receive cytarabine IT monthly for 12 months. (bioportfolio.com)
  • doses
  • Based on results from Phase I, the 0.03, 0.1 and 0.2 mg/kg single doses of velafermin (CG53135) are currently being evaluated in a randomized, double- blind, placebo-controlled, multi-center Phase II clinical trial for the prevention of OM in approximately 200 patients receiving HDCT followed by AHSCT. (rxpgnews.com)